eXoZymes Selects Curia for NCT Commercial Manufacturing

eXoZymes, a company pioneering AI-enhanced enzymes to transform abundant feedstocks into valuable nutraceuticals and novel medicines, has selected Curia Global Inc. as its commercial-scale manufacturing partner for its proprietary NCT (Novel Chemical Technology) manufacturing process. The collaboration is set to commence in the fourth quarter of 2026, with a focus on scaling the NCT process to establish a roadmap for larger-scale production in 2027.

According to eXoZymes, the agreement with Curia marks a significant step in advancing its NCT manufacturing process from successful pilot-scale validation to commercial manufacturing. "We are advancing the work required to establish the manufacturing pathway and supply chain to support NCT's planned commercial launch," said Damien Perriman, Chief Commercial Officer of eXoZymes. "The Curia engagement establishes the manufacturing foundation required to support commercial customer qualification, future supply agreements, and the planned market introduction of NCT."

Under the agreement, eXoZymes will transfer its NCT manufacturing process to Curia, which will scale the process at its facilities in León, Spain, and Rozzano, Italy. The program includes cross-validation of eXoZymes' proprietary enzyme fermentation, cell-free reaction, and purification processes to support larger-scale and eventual commercial manufacturing. Additionally, the program will involve process modeling and engineering analysis to define a recommended path to larger-scale manufacturing, further de-risking eXoZymes' route to commercial NCT supply.

Jamie Grabowski, President of R&D at Curia, expressed pride in partnering with eXoZymes. "Curia is proud to support eXoZymes as they advance NCT toward commercialization. Our facilities in León and Rozzano offer deep expertise in technology transfer, process development, and manufacturing, and they are well positioned to support this innovative program and help establish a reliable route to larger-scale NCT production."

Paul Opgenorth, PhD, VP of Development and co-founder of eXoZymes, elaborated on the significance of the transfer. "We have demonstrated the NCT process at pilot scale and substantially improved its productivity and economics. Transferring our entire integrated process, from enzyme production through the cell-free NCT reaction to product purification, into a commercial manufacturing environment represents an important validation of its maturity."

Both companies are optimistic about the potential of the NCT process. "eXoZymes' platform is designed to replace inefficient extraction and petrochemical processes with a scalable way to produce high-value molecules for nutraceutical and pharmaceutical markets," stated Opgenorth. "The collaboration with Curia will help us establish a robust manufacturing foundation, enabling us to meet the growing demand for our innovative products."

The program is expected to progress during the fourth quarter of 2026, establishing the technical roadmap for subsequent larger-scale production in 2027. This move is part of eXoZymes' broader strategy to commercialize its biosolutions across NCT, cannabinoid analogs, and other high-value natural product molecules.

In conclusion, the partnership between eXoZymes and Curia is a crucial milestone in the development and commercialization of eXoZymes' NCT technology. As the process transitions from pilot to commercial scale, the collaboration aims to ensure a reliable and efficient manufacturing process, paving the way for the widespread availability of eXoZymes' innovative products.